Member Info for sharehunter3

France moved up again
nice buying there

France up today
buyers may be thinking sales update soon

BUYERS LOADING AT THIS PRICE

PREVIOUS POST NOT APRIL SALES FIGURES
30TH MARCH RNS

Sales and regulatory update
As of 27 March, Primerdesign has sold and received orders for over £17.8 million (€19.6 million) of its CE-Mark and research use only (RUO) COVID-19 tests. The rate of demand for the test continues to increase, and on 27 March, Primerdesign received its largest single order to date of £1.4 million (€1.5 million) from a new customer in India following emergency use approval of the test on 26 March 2020.

Novacyt is now selling its COVID-19 test to more than 80 countries and the Middle-East is becoming the strongest selling region, with orders of £1.6m (€1.8m) received in less than two weeks. The Company expects to sign further distribution partnerships during the next few weeks in this region and also expects to update on its progress in the US market following Emergency Use Authorization granted by the US Food and Drug Administration announced on 23 March 2020.

29TH ARRIL RNS
29 Aril rns

Sales
As of 28 April 2020, Primerdesign has sold, received orders for or has been contracted to deliver over £90 million (€103 million) of its COVID-19 test. This figure includes the contracted minimum amount of test orders from the recently signed supply agreement with the UK's Department of Health and Social Care and initial orders received to date from the collaboration with AstraZeneca, GSK and the University of Cambridge.

Novacyt is now supplying its COVID-19 test to more than 100 countries and approvals for the test have recently been received from Malaysia and Ecuador. The Company continues to increase its sales level into the US market and is evaluating potential options to further expand its presence in this important market.

CAN SEE THE PROGRESS WITH THE
RNS 30 TH MARCH
RNS 29TH APRIL
HOW MUCH PROGRESS FROM MARCH TO APRIL
LOOKING FORWARD TO SEE HOW MUCH PROGRESS WITH MAYS SALES UPDATE

30 th MARH SALES UPDATE

Sales and regulatory update
As of 27 March, Primerdesign has sold and received orders for over £17.8 million (€19.6 million) of its CE-Mark and research use only (RUO) COVID-19 tests. The rate of demand for the test continues to increase, and on 27 March, Primerdesign received its largest single order to date of £1.4 million (€1.5 million) from a new customer in India following emergency use approval of the test on 26 March 2020.

Novacyt is now selling its COVID-19 test to more than 80 countries and the Middle-East is becoming the strongest selling region, with orders of £1.6m (€1.8m) received in less than two weeks. The Company expects to sign further distribution partnerships during the next few weeks in this region and also expects to update on its progress in the US market following Emergency Use Authorization granted by the US Food and Drug Administration announced on 23 March 2020.

29 APRIL SALES UPDATE

Sales and regulatory update
As of 27 March, Primerdesign has sold and received orders for over £17.8 million (€19.6 million) of its CE-Mark and research use only (RUO) COVID-19 tests. The rate of demand for the test continues to increase, and on 27 March, Primerdesign received its largest single order to date of £1.4 million (€1.5 million) from a new customer in India following emergency use approval of the test on 26 March 2020.

Novacyt is now selling its COVID-19 test to more than 80 countries and the Middle-East is becoming the strongest selling region, with orders of £1.6m (€1.8m) received in less than two weeks. The Company expects to sign further distribution partnerships during the next few weeks in this region and also expects to update on its progress in the US market following Emergency Use Authorization granted by the US Food and Drug Administration announced on 23 March 2020.

EVEN TO LOOK AT THE PROGRESS
FROM MARCH TO APRIL
LOOKING FORWARD TO SEE HOW MUCH PROGRESS WITH MAYS SALES UPDATE

29 Aril rns

Sales
As of 28 April 2020, Primerdesign has sold, received orders for or has been contracted to deliver over £90 million (€103 million) of its COVID-19 test. This figure includes the contracted minimum amount of test orders from the recently signed supply agreement with the UK's Department of Health and Social Care and initial orders received to date from the collaboration with AstraZeneca, GSK and the University of Cambridge.

Novacyt is now supplying its COVID-19 test to more than 100 countries and approvals for the test have recently been received from Malaysia and Ecuador. The Company continues to increase its sales level into the US market and is evaluating potential options to further expand its presence in this important market.

if sales update this week
or another rns
be an interesting week
to see how much share price moves
now that supplying over 100 countries

thinking this share price might be back over £5 or even £6 or £ 7
as the sales updates are released
if £90 million when manufacturing around 4 million covid 19 testing kits per month

here with along term view
one look at the monthly income
never mind the potential annual income for this share
that's why I bought more last week again
I usually invest more in ftse shares
like a good dividend
with so much income coming into ncyt
thinking a dividend might be paid in the future at ncyt or a share buy back
using this low share price to add to my holdings

the vacancies show how much progress
Wilson 63 thanks for posting links

will be watching for rns this week with sales update
this week might be the week that share price moves back up again

https://news.sky.com/story/coronavirus-has-mutated-into-more-than-30-strains-say-scientists-in-china-11976380

so sad to read of the deaths and illness from Covid 19 at the care homes
and yet

Novacyt is now supplying its COVID-19 test to more than 100 countries
hoping more might be used to test staff and residents at care homes in UK

Care home coronavirus testing pledge in tatters as just 21 ...
https://www.mirror.co.uk/news/uk-news/care-home-coronavirus-testing...
12 hours ago · Care home coronavirus testing pledge in tatters as just 21% have been checked - Mirror Online Only 21% of people living in care home have been tested for the coronavirus since the pandemic began,...

one of times France fell quite a bit
we got good news that week and a rise
thinking this week might see sales update
so hoping for a good week this week

another good mover up yesterday here
see you also at ncyt
share price dropped nicely there with their covid 19 testing kit manufacturing increasing
and the money they now coming in each month ,thinking it due a move up again
hoping Tuesday might see more of a move up here at Y U
hoping for to see share buy here in the future

In early January 2020, Novacyt commenced the development of a new test in response to the emerging novel coronavirus (COVID-19) threat emerging from China. Primerdesign launched its test in late January 2020 to become one of the world's first molecular tests for the SARS-CoV-2 virus. The test was the first to achieve CE-IVD status and was subsequently approved for emergency use by the US Food and Drug Administration, the World Health Organisation and other regulatory bodies. The Company quickly established the need to develop significant manufacturing capacity and today has eight dedicated manufacturing sites capable of producing COVID-19 tests at an output rate of more than ten million tests per month, which Novacyt expects to achieve from June 2020 onwards. Through its investment in raw materials and manufacturing, the Company is now in a position to service significant and expected growth in demand for its COVID-19 test.

Graham Mullis, Chief Executive Officer of Novacyt, commented:
"The visibility of the sales order book is transformational for the business and it is becoming increasingly clear that this exceptional demand for our COVID-19 test could continue for some months. As a result, we continue to ensure we have significant capacity and flexibility in the manufacturing of our COVID-19 test.

"I am proud that innovation remains at the heart of the business and the forthcoming launch of our Exsig™ Free extraction kit will address a significant market need to increase testing availability and throughput. This is a challenging time for Novacyt but the transformation of our financial performance and our position as a market leader in clinical diagnostics means we are confident in the long-term prospects of the business."

some other covid shares finished blue
ncyt red again today
will June be the month to start to see ncyt start to move back up again

Update on US OEM thinking soon

another sales update thinking soon

Update on Partnership with AZ, GSK & University of Cambridge

Graham Mullis, Chief Executive Officer of Novacyt, commented:
"The visibility of the sales order book is transformational for the business and it is becoming increasingly clear that this exceptional demand for our COVID-19 test could continue for some months. As a result, we continue to ensure we have significant capacity and flexibility in the manufacturing of our COVID-19 test.

"I am proud that innovation remains at the heart of the business and the forthcoming launch of our Exsig™ Free extraction kit will address a significant market need to increase testing availability and throughput. This is a challenging time for Novacyt but the transformation of our financial performance and our position as a market leader in clinical diagnostics means we are confident in the long-term prospects of the business."
·

· .

·

be good if news next week

buyers moving in or back in before end of trading
good volume of buyers now showing